Vyjuvek Growth Powers Krystal Biotech's (KRYS) Huge Upward Analyst Target Price Revision [Yahoo! Finance]
Krystal Biotech (NASDAQ:KRYS) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Krystal Biotech (NASDAQ:KRYS) had its price target raised by analysts at Bank of America Corporation from $288.00 to $318.00. They now have a "buy" rating on the stock.
What Does Wall Street Think About Krystal Biotech (KRYS)? [Yahoo! Finance]
Stock Market Today, Jan. 16: ImmunityBio Soars After Anktiva Revenue Jumps 700 Percent Year Over Year [Yahoo! Finance]